These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 16465841)

  • 21. [Lower and lower cholesterol targets increase adverse effects].
    Hjemdahl P; Allhammar A; Heaton C; Hulting J; Kahan T; Malmström R; Martinsson A; Rücker F; Schenck-Gustafsson K; Schwieler J; Törnerud M; Wettermark B; ;
    Lakartidningen; 2009 Sep 30-Oct 6; 106(40):2550-1. PubMed ID: 19908628
    [No Abstract]   [Full Text] [Related]  

  • 22. [Dual inhibition of cholesterol using the drug combination ezetimibe/simvastatin?].
    Vaverková H
    Vnitr Lek; 2007 Apr; 53(4):421-7. PubMed ID: 17578178
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lipids and cardiovascular risk reduction -- new targets, new challenges.
    Jackson G
    Int J Clin Pract; 2005 Jun; 59(6):617-8. PubMed ID: 15924585
    [No Abstract]   [Full Text] [Related]  

  • 24. Drug insight: the role of statins in combination with ezetimibe to lower LDL cholesterol.
    Gotto AM; Farmer JA
    Nat Clin Pract Cardiovasc Med; 2006 Dec; 3(12):664-72. PubMed ID: 17122799
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Should women with normal cholesterol be taking a statin? A major study suggests that statins also quell inflammation. Now what?
    Harv Womens Health Watch; 2009 Feb; 16(6):1-3. PubMed ID: 19297742
    [No Abstract]   [Full Text] [Related]  

  • 26. [Statin cuts cardiovascular risk in half].
    Einecke D
    MMW Fortschr Med; 2008 Dec; 150(49-50):12-3. PubMed ID: 19133364
    [No Abstract]   [Full Text] [Related]  

  • 27. [Treatment of hypercholesterolemia--lower is better].
    Haghfelt TH
    Ugeskr Laeger; 2006 Feb; 168(9):900-1. PubMed ID: 16513052
    [No Abstract]   [Full Text] [Related]  

  • 28. [Lowering of LDL cholesterol prevents cardiovascular diseases. "Normal values" are too high--treatment time is a crucial factor].
    Rudling M
    Lakartidningen; 2006 Oct 25-31; 103(43):3278-82. PubMed ID: 17117659
    [No Abstract]   [Full Text] [Related]  

  • 29. Examination of encapsulated phytosterol ester supplementation on lipid indices associated with cardiovascular disease.
    Earnest CP; Mikus CR; Lemieux I; Arsenault BJ; Church TS
    Nutrition; 2007 Sep; 23(9):625-33. PubMed ID: 17644340
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy, safety and LDL-C goal attainment of ezetimibe 10 mg-simvastatin 20 mg vs. placebo-simvastatin 20 mg in UK-based adults with coronary heart disease and hypercholesterolaemia.
    Patel JV; Hughes EA
    Int J Clin Pract; 2006 Aug; 60(8):914-21. PubMed ID: 16893434
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enhanced LDL-C reduction: lower is better. Does it matter how?
    Viljoen A; Wierzbicki AS
    Int J Clin Pract; 2008 Apr; 62(4):518-20. PubMed ID: 18324945
    [No Abstract]   [Full Text] [Related]  

  • 32. [Misleading advice on cholesterol reduction].
    Ravnskov U
    Lakartidningen; 2006 Feb 22-28; 103(8):568; discussion 569. PubMed ID: 16570784
    [No Abstract]   [Full Text] [Related]  

  • 33. [Heart Protection Study].
    Larsen ML; Hildebrandt PR
    Ugeskr Laeger; 2002 Jan; 164(3):348. PubMed ID: 11816337
    [No Abstract]   [Full Text] [Related]  

  • 34. Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study).
    LaRosa JC; Grundy SM; Kastelein JJ; Kostis JB; Greten H;
    Am J Cardiol; 2007 Sep; 100(5):747-52. PubMed ID: 17719314
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Sequelae of the JUPITER study. What is changing in primary prevention? (interview by Dr. med. Dirk Einecke)].
    Parhofer K
    MMW Fortschr Med; 2008 Dec; 150(49-50):14. PubMed ID: 19130769
    [No Abstract]   [Full Text] [Related]  

  • 36. Lipid-altering efficacy of ezetimibe/simvastatin 10/40 mg compared with doubling the statin dose in patients admitted to the hospital for a recent coronary event: the INFORCE study.
    Reckless JP; Henry P; Pomykaj T; Lim ST; Massaad R; Vandormael K; Johnson-Levonas AO; Lis K; Brudi P; Allen C
    Int J Clin Pract; 2008 Apr; 62(4):539-54. PubMed ID: 18266852
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictors of uncontrolled hyperlipidaemia in high-risk ambulatory patients in primary care.
    Hildemann S; Karmann B; Pittrow D; Barho C; Darius H; Bode C
    Curr Med Res Opin; 2008 Jun; 24(6):1659-68. PubMed ID: 18457604
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Plant stanoles in the prevention of cardiovascular diseases. Requirements regarding hard terminal points of soft margarines].
    Astrup AV; Ovesen LF; Stender S
    Ugeskr Laeger; 2001 Nov; 163(46):6437-9. PubMed ID: 11816923
    [No Abstract]   [Full Text] [Related]  

  • 39. The effects of low-dose simvastatin and ezetimibe compared to high-dose simvastatin alone on post-fat load endothelial function in patients with metabolic syndrome: a randomized double-blind crossover trial.
    Olijhoek JK; Hajer GR; van der Graaf Y; Dallinga-Thie GM; Visseren FL
    J Cardiovasc Pharmacol; 2008 Aug; 52(2):145-50. PubMed ID: 18670365
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Dual cholesterol inhibition. More high risk patients achieve LDL cholesterol values below 100 mg/dl].
    MMW Fortschr Med; 2008 Jun; 150(23):39. PubMed ID: 18575369
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.